Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Ethnic-specific prevalence of peripheral arterial disease in the United States.Am J Prev Med. 2007; 32: 328-333
- Lower-extremity endovascular interventions for Medicare beneficiaries: comparative effectiveness as a function of provider specialty.J Vasc Interv Radiol. 2012; 23: 3-9.e1-14
- Outcomes of endovascular lower extremity interventions depend more on indication than physician specialty.J Vasc Surg. 2014; 59: 376-383.e3
- Frequency of care and mortality following an incident diagnosis of peripheral artery disease in the inpatient or outpatient setting: the ARIC (Atherosclerosis Risk in Communities) study.J Am Heart Assoc. 2018; 7e007332
- Do differences in hospital and surgeon quality explain racial disparities in lower-extremity vascular amputations?.Ann Surg. 2009; 250: 424-431
- Validity of peripheral arterial disease diagnoses in the Danish National Patient Registry.Eur J Vasc Endovasc Surg. 2017; 53: 679-685
- Administrative data are not sensitive for the detection of peripheral artery disease in the community.Vasc Med. 2016; 21: 331-336
- Model-based algorithms for detecting peripheral artery disease using administrative data from an electronic health record data system: algorithm development study.JMIR Med Inform. 2020; 8: e18542
- Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors.Med Care. 2005; 43: 480-485
- Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.Med Care. 2005; 43: 1130-1139
- Type 2 diabetes mellitus is a strong predictor of LDL cholesterol target achievement in patients with peripheral artery disease.J Diabetes Complications. 2020; 34107692
Agency for Healthcare Research and Quality. Chartbook on Access to Health Care. Available at: https://www.ahrq.gov/research/findings/nhqrdr/chartbooks/access/elements.html. Accessed November 17, 2020.
Funding: EHW is supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number F32HL151181. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Doris Duke Charitable Foundation provided a Clinical Scientist Development Grant to WSJ to complete this work. The Doris Duke Charitable Foundation did not have any involvement in this research or manuscript preparation.
Conflicts of Interest: LHC reports research support from Bayer, Akebia, Sanofi, Janssen, and Amgen and consulting for Regeneron, NFL Players Association. MRP reports research grants from Janssen, Bayer, NHLBI, Heartflow, and Phillips and serving on advisory board and consulting for Bayer, Janssen, and Heartflow. WSJ reports research support for Boehringer Ingelheim, Doris Duke Charitable Foundation, National Institute of Health, Patient-Centered Outcomes Research Institute, and serving on advisory board for Bayer, Bristol-Myers Squibb, and Janssen Pharmaceuticals. EHW, CBF, DIN, SJL, MMS, MAG, NCH, BOB, RCS, AJB, and CL report none.
Authorship: All authors had access to the data and a role in writing this manuscript.